| Chronic Obstructive Airway Disease
Bevespi Aerosphere vs Dalisrep
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Bevespi Aerosphere vs Daliresp with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsDaliresp has a higher rate of injection site reactions vs Bevespi Aerosphere based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Daliresp but not Bevespi Aerosphere, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Bevespi Aerosphere
Daliresp
At A Glance
Oral inhalation
Twice daily
LAMA/LABA combination
Oral
Daily
PDE4 inhibitor
Indications
- Chronic Obstructive Airway Disease
- Chronic Obstructive Airway Disease
Dosing
Chronic Obstructive Airway Disease 2 inhalations (glycopyrrolate 18 mcg and formoterol fumarate 9.6 mcg) twice daily in the morning and evening by oral inhalation; do not exceed two inhalations twice daily.
Chronic Obstructive Airway Disease Maintenance dose: 500 mcg once daily, with or without food; an optional titration of 250 mcg once daily for the first 4 weeks may reduce discontinuation rates, but 250 mcg is not the effective therapeutic dose.
Contraindications
- Use of a long-acting beta2-adrenergic agonist (LABA), including formoterol fumarate, without an inhaled corticosteroid in patients with asthma
- Hypersensitivity to glycopyrrolate, formoterol fumarate, or any component of the product
- Moderate to severe liver impairment (Child-Pugh B or C)
Adverse Reactions
Most common (>=2%) Cough, urinary tract infection
Serious Paradoxical bronchospasm, hypersensitivity reactions including anaphylaxis, cardiovascular effects, worsening of narrow-angle glaucoma, worsening of urinary retention
Postmarketing Hypersensitivity, urinary retention
Most common (>=2%) Diarrhea, weight decreased, nausea, headache, back pain, influenza, insomnia, dizziness, decreased appetite
Serious Diarrhea, atrial fibrillation, lung cancer, prostate cancer, acute pancreatitis, acute renal failure
Postmarketing Hypersensitivity reactions (angioedema, urticaria, rash), gynecomastia
Pharmacology
BEVESPI AEROSPHERE combines glycopyrrolate, a long-acting anticholinergic (LAMA) that inhibits M3 muscarinic receptors in airway smooth muscle to produce bronchodilation, with formoterol fumarate, a long-acting selective beta2-adrenoceptor agonist (LABA) that stimulates adenyl cyclase to increase cyclic AMP, relaxing bronchial smooth muscle and inhibiting mediator release from mast cells.
Roflumilast and its active metabolite (roflumilast N-oxide) are selective inhibitors of phosphodiesterase 4 (PDE4); inhibition of PDE4 leads to accumulation of intracellular cyclic AMP in lung tissue, which is thought to underlie its therapeutic action in COPD.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Bevespi Aerosphere
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (5/12) · Qty limit (9/12)
Daliresp
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Bevespi Aerosphere
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (6/8)
Daliresp
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (7/8)
Humana
Bevespi Aerosphere
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Daliresp
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Bevespi Aerosphere.
No savings programs available for Daliresp.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Bevespi AerosphereView full Bevespi Aerosphere profile
DalirespView full Daliresp profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.